Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer

por Riess, Jonathan W., Lara, Primo N., Gandara, David R.
Publicado 2016

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

por Li, Tianhong, Christensen, Scott D., Frankel, Paul H., Margolin, Kim A., Agarwala, Sanjiv S., Luu, Thehang, Mack, Philip C., Lara, Primo N., Gandara, David R.
Publicado 2010

A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer

por Chen, Yuhchyau, Moon, James, Pandya, Kishan J., Lau, Derick H. M., Kelly, Karen, Hirsch, Fred R., Gaspar, Laurie E., Redman, Mary, Gandara, David R.
Publicado 2013

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed...

por Semrad, Thomas J, Groshen, Susan, Luo, Chunqiao, Pal, Sumanta, Vaishampayan, Ulka, Joshi, Monika, Quinn, David I., Mack, Philip C., Gandara, David R., Lara, Primo N.
Publicado 2019

Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival

por Fahrmann, Johannes F., Grapov, Dmitry, Phinney, Brett S., Stroble, Carol, DeFelice, Brian C., Rom, William, Gandara, David R., Zhang, Yanhong, Fiehn, Oliver, Pass, Harvey, Miyamoto, Suzanne
Publicado 2016

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

por Lara, Matthew S., Gubens, Matthew A., Bacaltos, Bianca, Daran, Lea, Lim, Steffany L., Li, Tianhong, Gandara, David R., Bivona, Trever G., Riess, Jonathan W., Blakely, Collin M.
Publicado 2022

Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry

por Miyamoto, Suzanne, Taylor, Sandra L., Barupal, Dinesh K., Taguchi, Ayumu, Wohlgemuth, Gert, Wikoff, William R., Yoneda, Ken Y., Gandara, David R., Hanash, Samir M., Kim, Kyoungmi, Fiehn, Oliver
Publicado 2015

Integrated metabolomics and proteomics highlight altered nicotinamide and polyamine pathways in lung adenocarcinoma

por Fahrmann, Johannes F., Grapov, Dmitry, Wanichthanarak, Kwanjeera, DeFelice, Brian C., Salemi, Michelle R., Rom, William N., Gandara, David R., Phinney, Brett S., Fiehn, Oliver, Pass, Harvey, Miyamoto, Suzanne
Publicado 2017

A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)

por Bepler, Gerold, Zinner, Ralph G, Moon, James, Calhoun, Royce, Kernstine, Kemp, Williams, Charles C, Mack, Philip C, Oliveira, Vasco, Zheng, Zhong, Stella, Philip J, Redman, Mary W, Gandara, David R
Publicado 2014

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

por McCoach, Caroline E., Yu, Aiming, Gandara, David R., Riess, Jonathan W., Vang, Daniel P., Li, Tiahong, Lara, Primo N., Gubens, Matthew, Lara, Frances, Mack, Philip C., Beckett, Laurel A., Kelly, Karen
Publicado 2021

American Society of Clinical Oncology’s Global Oncology Leadership Task Force: Findings and Actions

por Hortobagyi, Gabriel N., Pyle, Doug, Cazap, Eduardo L., El Saghir, Nagi S., Shulman, Lawrence N., Lyman, Gary H., Schnipper, Lowell E., Adebamowo, Clement Adebayo, Gandara, David R., Vose, Julie, Wong, Sandra L., Yu, Peter
Publicado 2017

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

por Mack, Philip C., Banks, Kimberly C., Espenschied, Carin R., Burich, Rebekah A., Zill, Oliver A., Lee, Christine E., Riess, Jonathan W., Mortimer, Stefanie A., Talasaz, AmirAli, Lanman, Richard B., Gandara, David R.
Publicado 2020

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

por Riess, Jonathan W, Reckamp, Karen L, Frankel, Paul, Longmate, Jeffrey, Kelly, Karen A, Gandara, David R, Weipert, Caroline M, Raymond, Victoria M, Keer, Harold N, Mack, Philip C, Newman, Edward M, Lara, Primo N
Publicado 2021

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

por Reckamp, Karen L., Redman, Mary W., Dragnev, Konstantin H., Minichiello, Katherine, Villaruz, Liza C., Faller, Bryan, Al Baghdadi, Tareq, Hines, Susan, Everhart, Leah, Highleyman, Louise, Papadimitrakopoulou, Vassiliki, Gandara, David R., Kelly, Karen, Herbst, Roy S.
Publicado 2022

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy

por Pan, Chong-xian, Zhang, Hongyong, Tepper, Clifford G., Lin, Tzu-yin, Davis, Ryan R., Keck, James, Ghosh, Paramita M., Gill, Parkash, Airhart, Susan, Bult, Carol, Gandara, David R., Liu, Edison, de Vere White, Ralph W.
Publicado 2015

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epider...

por Reckamp, Karen L., Frankel, Paul H., Ruel, Nora, Mack, Philip C., Gitlitz, Barbara J., Li, Tianhong, Koczywas, Marianna, Gadgeel, Shirish M., Cristea, Mihaela C., Belani, Chandra P., Newman, Edward M., Gandara, David R., Lara, Primo N.
Publicado 2019

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer

por Chen, Justin A., Huynh, Jasmine C., Wu, Chun-Yi, Yu, Ai-Ming, Matsukuma, Karen, Semrad, Thomas J., Gandara, David R., Li, Tianhong, Riess, Jonathan W., Tam, Kit, Mack, Philip C., Martinez, Anthony, Mahaffey, Nichole, Kelly, Karen L., Kim, Edward J.
Publicado 2022

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

por Ranganath, Harsha, Jain, Amit L., Smith, Justin R., Ryder, Julie, Chaudry, Amina, Miller, Emily, Hare, Felicia, Valasareddy, Poojitha, Seitz, Robert S., Hout, David R., Varga, Matthew G., Schweitzer, Brock L., Nielsen, Tyler J., Mullins, Janice, Ross, Douglas T., Gandara, David R., Vidal, Gregory A.
Publicado 2022

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

por Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Publicado 2021

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400...

por Leighl, Natasha B, Redman, Mary W, Rizvi, Naiyer, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Wade, James L, Irvin, William J, Reddy, Sreekanth C, Crawford, Jeffrey, Bradley, Jeffrey D, Stinchcombe, Thomas E, Ramalingam, Suresh S, Miao, Jieling, Minichiello, Katherine, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A, Kelly, Karen, Gandara, David R
Publicado 2021